Back to results
US 2023/0265518 A1Published application
Methods and compositions relating to oprm1 dna methylation for personalized pain management
AssigneeChildren's Hospital Medical Center
InventorsVidya Chidambaran, Senthilkumar Sadhasivam, Hong Ji, Lisa Martin
Life of this patent
Estimating the term…
Abstract
The disclosure relates to methods for pain management in the perioperative context, particularly through the use of the DNA methylation status of the human OPRM1 gene as a biomarker for increased susceptibility to perioperative pain, and related methods and compositions.
Claims22
1-26. (canceled)
A method for the prevention of an atypical opioid response in a human subject in need thereof, the method comprising
- assaying, in vitro, a biological sample from the subject to determine a methylation status of at least one CpG site in the human mu-1 opioid receptor gene (OPRM1),
- wherein the at least one CpG site in OPRM1 is selected from the group consisting of CpG sites 1, 3, 4, 9, 11, 13, 17, and 22 as defined in Table 4,
- identifying the subject as one who is susceptible to an atypical opioid response where the subject has a methylation status of “methylated” at the at least one CpG site, and
- administering to the subject identified as susceptible to an atypical opioid response a demethylating agent, an inhibitor of the repressor element-1 silencing transcription factor (REST) and/or a regimen of multimodal analgesia for perioperative pain management.
1 more element
Dependencies are inferred from the claim text.